vs
Prestige Consumer Healthcare Inc.（PBH）とPROGRESS SOFTWARE CORP（PRGS）の財務データ比較。上の社名をクリックして会社を切り替えられます
Prestige Consumer Healthcare Inc.の直近四半期売上が大きい（$283.4M vs $252.7M、PROGRESS SOFTWARE CORPの約1.1倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs 10.2%、差は6.3%）。PROGRESS SOFTWARE CORPの前年同期比売上増加率が高い（17.5% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $59.9M）。過去8四半期でPROGRESS SOFTWARE CORPの売上複合成長率が高い（17.0% vs 1.2%）
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
プログレスソフトウェアコーポレーションは、アプリケーション開発プラットフォーム、データ接続ツール、デジタルエクスペリエンスソリューションなどの企業向けソフトウェアを開発・販売しています。金融、医療、製造、小売など世界中の多様な業界の顧客にサービスを提供し、業務効率化と高性能業務アプリの構築を支援しています。
PBH vs PRGS — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $283.4M | $252.7M |
| 純利益 | $46.7M | $25.7M |
| 粗利率 | 55.5% | 81.6% |
| 営業利益率 | 29.1% | 15.2% |
| 純利益率 | 16.5% | 10.2% |
| 売上前年比 | -2.4% | 17.5% |
| 純利益前年比 | -23.5% | 2144.6% |
| EPS（希薄化後） | $0.97 | $0.59 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $283.4M | $252.7M | ||
| Q3 25 | $274.1M | $249.8M | ||
| Q2 25 | $249.5M | $237.4M | ||
| Q1 25 | $296.5M | $238.0M | ||
| Q4 24 | $290.3M | $215.0M | ||
| Q3 24 | $283.8M | $178.7M | ||
| Q2 24 | $267.1M | $175.1M | ||
| Q1 24 | $277.0M | $184.7M |
| Q4 25 | $46.7M | $25.7M | ||
| Q3 25 | $42.2M | $19.4M | ||
| Q2 25 | $47.5M | $17.0M | ||
| Q1 25 | $50.1M | $10.9M | ||
| Q4 24 | $61.0M | $1.1M | ||
| Q3 24 | $54.4M | $28.5M | ||
| Q2 24 | $49.1M | $16.2M | ||
| Q1 24 | $49.5M | $22.6M |
| Q4 25 | 55.5% | 81.6% | ||
| Q3 25 | 55.3% | 81.0% | ||
| Q2 25 | 56.2% | 80.1% | ||
| Q1 25 | 57.3% | 80.6% | ||
| Q4 24 | 55.5% | 83.0% | ||
| Q3 24 | 55.5% | 83.7% | ||
| Q2 24 | 54.7% | 81.7% | ||
| Q1 24 | 54.8% | 82.2% |
| Q4 25 | 29.1% | 15.2% | ||
| Q3 25 | 29.1% | 17.6% | ||
| Q2 25 | 28.8% | 16.3% | ||
| Q1 25 | 29.8% | 13.6% | ||
| Q4 24 | 31.7% | 10.0% | ||
| Q3 24 | 29.7% | 22.6% | ||
| Q2 24 | 27.0% | 15.5% | ||
| Q1 24 | 29.7% | 19.0% |
| Q4 25 | 16.5% | 10.2% | ||
| Q3 25 | 15.4% | 7.8% | ||
| Q2 25 | 19.0% | 7.2% | ||
| Q1 25 | 16.9% | 4.6% | ||
| Q4 24 | 21.0% | 0.5% | ||
| Q3 24 | 19.2% | 15.9% | ||
| Q2 24 | 18.4% | 9.2% | ||
| Q1 24 | 17.9% | 12.3% |
| Q4 25 | $0.97 | $0.59 | ||
| Q3 25 | $0.86 | $0.44 | ||
| Q2 25 | $0.95 | $0.39 | ||
| Q1 25 | $1.00 | $0.24 | ||
| Q4 24 | $1.22 | $0.01 | ||
| Q3 24 | $1.09 | $0.65 | ||
| Q2 24 | $0.98 | $0.37 | ||
| Q1 24 | $0.98 | $0.51 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $62.4M | $94.8M |
| 総負債低いほど良い | $1.0B | $1.4B |
| 株主資本純資産 | $1.8B | $478.3M |
| 総資産 | $3.5B | $2.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.56× | 2.93× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $62.4M | $94.8M | ||
| Q3 25 | $119.1M | $99.0M | ||
| Q2 25 | $139.5M | $102.0M | ||
| Q1 25 | $97.9M | $124.2M | ||
| Q4 24 | $50.9M | $118.1M | ||
| Q3 24 | $51.5M | $232.7M | ||
| Q2 24 | $34.3M | $190.4M | ||
| Q1 24 | $46.5M | $133.2M |
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $993.1M | $1.4B | ||
| Q2 25 | $992.7M | $1.5B | ||
| Q1 25 | $992.4M | $1.5B | ||
| Q4 24 | $992.0M | $1.5B | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $1.8B | $478.3M | ||
| Q3 25 | $1.8B | $477.7M | ||
| Q2 25 | $1.9B | $452.7M | ||
| Q1 25 | $1.8B | $431.8M | ||
| Q4 24 | $1.8B | $438.8M | ||
| Q3 24 | $1.7B | $425.6M | ||
| Q2 24 | $1.7B | $401.7M | ||
| Q1 24 | $1.7B | $461.7M |
| Q4 25 | $3.5B | $2.5B | ||
| Q3 25 | $3.4B | $2.4B | ||
| Q2 25 | $3.4B | $2.4B | ||
| Q1 25 | $3.4B | $2.5B | ||
| Q4 24 | $3.3B | $2.5B | ||
| Q3 24 | $3.3B | $1.6B | ||
| Q2 24 | $3.3B | $1.6B | ||
| Q1 24 | $3.3B | $1.5B |
| Q4 25 | 0.56× | 2.93× | ||
| Q3 25 | 0.54× | 2.97× | ||
| Q2 25 | 0.54× | 3.22× | ||
| Q1 25 | 0.54× | 3.50× | ||
| Q4 24 | 0.55× | 3.48× | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.68× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $78.3M | $62.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $75.3M | $59.9M |
| FCFマージンFCF / 売上 | 26.6% | 23.7% |
| 設備投資強度設備投資 / 売上 | 1.1% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 1.68× | 2.44× |
| 直近12ヶ月FCF直近4四半期 | $267.2M | $229.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $78.3M | $62.8M | ||
| Q3 25 | $57.5M | $73.4M | ||
| Q2 25 | $79.0M | $30.0M | ||
| Q1 25 | $61.8M | $68.9M | ||
| Q4 24 | $65.1M | $19.7M | ||
| Q3 24 | $69.8M | $57.7M | ||
| Q2 24 | $54.8M | $63.7M | ||
| Q1 24 | $66.9M | $70.5M |
| Q4 25 | $75.3M | $59.9M | ||
| Q3 25 | $55.4M | $72.4M | ||
| Q2 25 | $78.2M | $29.5M | ||
| Q1 25 | $58.4M | $67.7M | ||
| Q4 24 | $63.5M | $16.8M | ||
| Q3 24 | $67.8M | $56.6M | ||
| Q2 24 | $53.6M | $62.7M | ||
| Q1 24 | $63.8M | $70.2M |
| Q4 25 | 26.6% | 23.7% | ||
| Q3 25 | 20.2% | 29.0% | ||
| Q2 25 | 31.3% | 12.4% | ||
| Q1 25 | 19.7% | 28.4% | ||
| Q4 24 | 21.9% | 7.8% | ||
| Q3 24 | 23.9% | 31.7% | ||
| Q2 24 | 20.1% | 35.8% | ||
| Q1 24 | 23.0% | 38.0% |
| Q4 25 | 1.1% | 1.1% | ||
| Q3 25 | 0.8% | 0.4% | ||
| Q2 25 | 0.3% | 0.2% | ||
| Q1 25 | 1.2% | 0.5% | ||
| Q4 24 | 0.5% | 1.3% | ||
| Q3 24 | 0.7% | 0.6% | ||
| Q2 24 | 0.4% | 0.5% | ||
| Q1 24 | 1.1% | 0.2% |
| Q4 25 | 1.68× | 2.44× | ||
| Q3 25 | 1.36× | 3.78× | ||
| Q2 25 | 1.66× | 1.76× | ||
| Q1 25 | 1.23× | 6.30× | ||
| Q4 24 | 1.07× | 17.13× | ||
| Q3 24 | 1.28× | 2.03× | ||
| Q2 24 | 1.12× | 3.93× | ||
| Q1 24 | 1.35× | 3.11× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
